Oncolytic virotherapy for hematological malignancies

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Bais, Swarna ^a   Bartee, Eric ^a   Rahman, Masmudur M ^a   McFadden, Grant ^a   Cogle, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIEVIRUS; MEASLES VIRUS; MYXOMA VIRUS; ORTHOREOVIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84862797578     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/186512     Document Type: Review

References (76)

1. Mueller B. U., Pabst T., Fos J., Petkovic V., Fey M. F., Asou N., Buergi U., Tenen D. G., ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006 107 8 3330 3338 2-s2.0-33645734361 10.1182/blood-2005-07-3068
2. Komrokji R. S., List A. F., Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematology/Oncology Clinics of North America 2010 24 2 377 388 2-s2.0-77950542156 10.1016/j.hoc.2010.02.013
3. Link D. C., Schuettpelz L. G., Shen D., Wang J., Walter M. J., Kulkarni S., Payton J. E., Ivanovich J., Goodfellow P. J., Le Beau M., Koboldt D. C., Dooling D. J., Fulton R. S., Bender R. H.F., Fulton L. L., Delehaunty K. D., Fronick C. C., Appelbaum E. L., Schmidt H., Abbott R., O'Laughlin M., Chen K., McLellan M. D., Varghese N., Nagarajan R., Heath S., Graubert T. A., Ding L., Ley T. J., Zambetti G. P., Wilson R. K., rwilson@wustl.edu Mardis E. R., Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. Journal of the American Medical Association 2011 305 15 1568 1576 10.1001/jama.2011.473
4. Ko M., Huang Y., Jankowska A. M., Pape U. J., Tahiliani M., Bandukwala H. S., An J., Lamperti E. D., Koh K. P., Ganetzky R., Liu X. S., Aravind L., Agarwal S., MacIejewski J. P., Rao A., Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010 468 7325 839 843 2-s2.0-78650175023 10.1038/nature09586
5. Itzykson R., Kosmider O., Cluzeau T., Mansat-De Mas V., Dreyfus F., Beyne-Rauzy O., Quesnel B., Vey N., Gelsi-Boyer V., Raynaud S., Preudhomme C., Adès L., Fenaux P., Fontenay M., michaela.fontenay@inserm.fr Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011 25 7 1147 1152 10.1038/leu.2011.71
6. Itzykson R., Thépot S., Eclache V., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., Vey N., Recher C., Boehrer S., Gardin C., Adès L., Fenaux P., pierre.fenaux@avc.aphp.fr Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011 25 7 1207 1209 10.1038/leu.2011.63
7. Welch J. S., Westervelt P., Ding L., Larson D. E., Klco J. M., Kulkarni S., Wallis J., Chen K., Payton J. E., Fulton R. S., Veizer J., Schmidt H., Vickery T. L., Heath S., Watson M. A., Tomasson M. H., Link D. C., Graubert T. A., DiPersio J. F., Mardis E. R., Ley T. J., Wilson R. K., rwilson@wustl.edu Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. Journal of the American Medical Association 2011 305 15 1577 1584 10.1001/jama.2011.497
8. Raaijmakers M. H. G. P., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J. A., Ebert B. L., Al-Shahrour F., Hasserjian R. P., Scadden E. O., Aung Z., Matza M., Merkenschlager M., Lin C., Rommens J. M., Scadden D. T., Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010 464 7290 852 857 2-s2.0-77950862042 10.1038/nature08851
9. Madlambayan G. J., Meacham A. M., Hosaka K., Mir S., Jorgensen M., Scott E. W., Siemann D. W., Cogle C. R., Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010 116 9 1539 1547 2-s2.0-77956324472 10.1182/blood-2009-06-230474
10. Sanders R. C. Jr., Slayton W. B., Cogle C. R., Fisher R. C., Scott E. W., Stem cell research. Paediatric Respiratory Reviews 2006 7 2 135 140 2-s2.0-33744523293 10.1016/j.prrv.2006.03.009 (Pubitemid 43812270)
11. McKenzie J. L., Takenaka K., Gan O. I., Doedens M., Dick J. E., Low rhodamine 123 retention identifies long-term human hematopoietic stem cells within the Lin-CD34+CD38- population. Blood 2007 109 2 543 545 2-s2.0-33846233298 10.1182/blood-2006-06-030270 (Pubitemid 46105951)
12. Goodrum F., Jordan C. T., Terhune S. S., High K., Shenk T., Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood 2004 104 3 687 695 2-s2.0-3242780176 10.1182/blood-2003- 12-4344 (Pubitemid 38970561)
13. Matsui W., Huff C. A., Wang Q., Malehorn M. T., Barber J., Tanhehco Y., Smith B. D., Civin C. I., Jones R. J., Characterization of clonogenic multiple myeloma cells. Blood 2004 103 6 2332 2336 2-s2.0-1542283717 10.1182/blood-2003- 09-3064 (Pubitemid 38326254)
14. Perrotti D., Jamieson C., Goldman J., Skorski T., Chronic myeloid leukemia: mechanisms of blastic transformation. Journal of Clinical Investigation 2010 120 7 2254 2264 2-s2.0-77954977940 10.1172/JCI41246
15. American Cancer Society, Cancer Facts & Figures 2011 Atlanta, Ga, USA The Society
16. Stewart A. K., Fonseca R., Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. Journal of Clinical Oncology 2005 23 26 6339 6344 2-s2.0-27244439379 10.1200/JCO.2005.05.023 (Pubitemid 46218844)
17. Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R., Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group. Journal of Clinical Oncology 2006 24 3 431 436 2-s2.0-33644831033 10.1200/JCO.2005.03.0221 (Pubitemid 46630462)
18. Rajkumar S. V., Jacobus S., Callander N. S., Fonseca R., Vesole D. H., Williams M. E., Abonour R., Siegel D. S., Katz M., Greipp P. R., Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology 2010 11 1 29 37 2-s2.0-73249146496 10.1016/S1470-2045(09)70284-0
19. Barlogie B., Attal M., Crowley J., van Rhee F., Szymonifka J., Moreau P., Durie B. G., Harousseau J. L., Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. Journal of Clinical Oncology 2010 28 7 1209 1214 2-s2.0-77949894706 10.1200/JCO.2009.25.6081
20. Gahrton G., Svensson H., Björkstrand B., Apperley J., Carlson K., Cavo M., Ferrant A., Fouillard L., Gratecos N., Gratwohl A., Guilhot F., Lambertenghi Deliliers G., Ljungman P., Masszi T., Milligan D. W., Powles R. L., Reiffers J., Samson J. D., Stoppa A. M., Vernant J. P., Volin L., Wallvik J., Syngeneic transplantation in multiple myeloma-a case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplantation 1999 24 7 741 745 (Pubitemid 29469274)
21. Lj Lazarevic V., vladimir.lazarevic@skane.se Hägglund H., Remberger M., Wahlin A., Hallböök H., Juliusson G., Kimby E., Malm C., Omar H., Johansson J. -E., Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden. Leukemia and Lymphoma 2011 52 1 69 71 10.3109/10428194.2010.520777
22. Fouillard L., Labopin M., Gratwohl A., Gluckman E., Frassoni F., Beelen D. W., Willemze R., Montserrat E., Blaise D., Atienza A. I., Sierra J., Santos M., Gorin N. C., Rocha V., Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica 2008 93 6 834 841 2-s2.0-44949235984 10.3324/haematol.11277 (Pubitemid 351821719)
23. Vogel W., Kopp H. G., Kanz L., Einsele H., Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. Journal of Cancer Research and Clinical Oncology 2005 131 4 214 218 2-s2.0-13744259293 10.1007/s00432-004-0635-y (Pubitemid 40238936)
24. Galimberti S., Morabito F., Guerrini F., Palumbo G. A., Azzará A., Martino M., Benedetti E., Di Raimondo F., Petrini M., Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. British Journal of Haematology 2003 120 3 405 412 2-s2.0-0037323884 10.1046/j.1365-2141.2003. 04106.x (Pubitemid 36241496)
25. Barbui A. M., Galli M., Dotti G., Belli N., Borleri G., Gritti G., Bellavita P., Viero P., Comotti B., Barbui T., Rambaldi A., Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. British Journal of Haematology 2002 116 1 202 210 2-s2.0-0036159893 10.1046/j.0007-1048.2001.03189.x (Pubitemid 34122082)
26. Friedberg J. W., Kim H., Li S., Neuberg D., Boyd K., Daley H., Fisher D. C., Gribben J. G., Spitzer T., Freedman A. S., Ex vivo B cell depletion using the Eligix B cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplantation 2003 32 7 681 686 2-s2.0-12444261811 10.1038/sj.bmt.1704212 (Pubitemid 37258623)
27. De Rosa L., Lalle M., Pandolfi A., Ruscio C., Amodeo R., Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission. Annals of Hematology 2002 81 10 575 581 2-s2.0-0036951457 10.1007/s00277-002-0528-6 (Pubitemid 36097043)
28. Galimberti S., Marasca R., Caracciolo F., Fazzi R., Papineschi F., Benedetti E., Guerrini F., Morabito F., Oliva E., Di Renzo N., Federico M., Petrini M., Torelli G., The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 2002 29 7 581 587 2-s2.0-0036100488 10.1038/sj/bmt/1703422 (Pubitemid 34537718)
29. McCann J. C., Kanteti R., Shilepsky B., Miller K. B., Sweet M., Schenkein D. P., High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation 1996 2 1 37 43 2-s2.0-0030073234 (Pubitemid 126488194)
30. Feller N., Van Der Pol M. A., Waaijman T., Weijers G. W.D., Westra G., Ossenkoppele G. J., Schuurhuis G. J., gj.schuurhuis@vumc.nl Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. Clinical Cancer Research 2005 11 13 4793 4801 10.1158/1078-0432.CCR-05-0031 (Pubitemid 41557200)
31. Miyamoto T., Nagafuji K., Harada M., Eto T., Fujisaki T., Kubota A., Akashi K., Mizuno S. I., Takenaka K., Kanaji T., Gondo H., Okamura T., Inaba S., Niho Y., Quantitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia. British Journal of Haematology 1995 91 1 132 138 2-s2.0-0029074805
32. Sandler E. S., esandler@nemours.org Homans A., Mandell L., Amylon M., Wall D. A., Devidas M., Buchanan G. R., Lipton J. M., Billett A. L., Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a Pediatric Oncology Group pilot feasibility study. Journal of Pediatric Hematology/Oncology 2006 28 4 210 215 10.1097/01.mph.0000212902.84146.81 (Pubitemid 43791828)
33. Atta J., Fauth F., Keyser M., Petershofen E., Weber C., Lippok G., Hoelzer D., Martin H., Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplantation 2000 25 1 97 104 2-s2.0-0033964343 (Pubitemid 30093163)
34. Leung W., Chen A. R., Klann R. C., Moss T. J., Davis J. M., Noga S. J., Cohen K. J., Friedman A. D., Small D., Schwartz C. L., Borowitz M. J., Wharam M. D., Paidas C. N., Long C. A., Karandish S., McMannis J. D., Kastan M. B., Civin C. I., Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplantation 1998 22 10 971 979 2-s2.0-0031723262 (Pubitemid 28543059)
35. Burchill S. A., Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Medical and Pediatric Oncology 2001 36 1 213 219
36. Schulze R., Schulze M., Wischnik A., Ehnle S., Doukas K., Behr W., Ehret W., Schlimok G., Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplantation 1997 19 12 1223 1228 2-s2.0-0030760349 (Pubitemid 27302732)
37. Vannucchi A. M., Bosi A., Glinz S., Pacini P., Linari S., Saccardi R., Alterini R., Rigacci L., Guidi S., Lombardini L., Longo G., Mariani M. P., Rossi-Ferrini P., Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. British Journal of Haematology 1998 103 3 610 617 2-s2.0-7844252268 10.1046/j.1365-2141. 1998.01027.x (Pubitemid 28545293)
38. Bokemeyer C., Gillis A. J.M., Pompe K., Mayer F., Metzner B., Schleucher N., Schleicher J., Pflugrad-Jauch G., Oosterhuis J. W., Kanz L., Looijenga L. H.J., Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. Journal of Clinical Oncology 2001 19 12 3029 3036 (Pubitemid 32565440)
39. Kasahara T., Hara N., Bilim V., Tomita Y., Saito K., Obara K., Takahashi K., Sequential detection of alphafetoprotein-bearing cells in blood stem cell fraction of germ cell tumour patients. British Journal of Cancer 2001 85 8 1119 1123 2-s2.0-0035914256 10.1054/bjoc.2001.2050 (Pubitemid 33052309)
40. Brenner M. K., Rill D. R., Moen R. C., Krance R. A., Mirro J., Anderson W. F., Ihle J. N., Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. The Lancet 1993 341 8837 85 86 2-s2.0-0027471156 10.1016/0140-6736(93)92560-G (Pubitemid 23028118)
41. Deisseroth A. B., Zu Z., Claxton D., Hanania E. G., Fu S., Ellerson D., Goldberg L., Thomas M., Janicek K., Anderson W. F., Hester J., Korbling M., Durett A., Moen R., Berenson R., Heimfeld S., Hamer J., Calvert L., Tibbits P., Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994 83 10 3068 3076 2-s2.0-0028219443 (Pubitemid 24142743)
42. Rill D. R., Santana V. M., Roberts W. M., Nilson T., Bowman L. C., Krance R. A., Heslop H. E., Moen R. C., Ihle J. N., Brenner M. K., Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994 84 2 380 383 2-s2.0-0028263529 (Pubitemid 24215933)
43. Motta M. R., Mangianti S., Rizzi S., Ratta M., Campanini E., Fortuna A., Fogli M., Tufa S., Lemoli R. M., Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies. Experimental Hematology 1997 25 12 1261 1269 2-s2.0-0030698255 (Pubitemid 27508874)
44. Shpall E. J., Jones R. B., Bast R. C., Rosner G. L., Vandermark R., Ross M., Affronti M. L., Johnston C., Eggleston S., Tepperburg M., Coniglio D., Peters W. P., 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. Journal of Clinical Oncology 1991 9 1 85 93 2-s2.0-0026015639
45. Abonour R., Scott K. M., Kunkel L. A., Robertson M. J., Hromas R., Graves V., Lazaridis E. N., Cripe L., Gharpure V., Traycoff C. M., Mills B., Srour E. F., Cornetta K., Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplantation 1998 22 10 957 963 2-s2.0-0031754533 (Pubitemid 28543057)
46. Spyridonidis A., Schmidt M., Bernhardt W., Papadimitriou A., Azemar M., Wels W., Groner B., Henschler R., Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood 1998 91 5 1820 1827 2-s2.0-0032031512 (Pubitemid 28110350)
47. Gee A., Moss T., Mansour V., Kulcinski D., Law P., Ishizawa L., Hardwick A., Large-scale immunomagnetic separation system for the removal of tumor cells from bone marrow. Progress in Clinical and Biological Research 1992 377 181 187 2-s2.0-0026620975
48. Cheson B. D., bdc4@georgetown.edu Monoclonal antibody therapy for B-cell malignancies. Seminars in Oncology 2006 33 2, supplement 5 2 14 10.1053/j.seminoncol.2006.01.024 (Pubitemid 44251035)
49. Goggins T. F., Chao N., Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease. Leukemia and Lymphoma 2003 44 11 1871 1879 2-s2.0-0242467358 10.1080/1042819031000119226 (Pubitemid 37369619)
50. Wang S. Y., Makl K. L., Chen L. Y., Tzeng C. H., Hu C. P., Chang C., Elimination of malignant tumor cells from human bone marrow using monoclonal antibodies and immunomagnetic beads. Anticancer Research 1993 13 6 A 2281 2285 2-s2.0-0027787830 (Pubitemid 24036364)
51. Kim M., Madlambayan G. J., Rahman M. M., Smallwood S. E., Meacham A. M., Hosaka K., Scott E. W., Cogle C. R., McFadden G., Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 2009 23 12 2313 2317 2-s2.0-74049127994
52. Au G. G., Lincz L. F., Enno A., Shafren D. R., Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. British Journal of Haematology 2007 137 2 133 141 2-s2.0-33947538023 10.1111/j.1365-2141.2007.06550.x (Pubitemid 46474719)
53. Shafren D. R., Dorahy D. J., Greive S. J., Burns G. F., Barry R. D., Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. Journal of Virology 1997 71 1 785 789 2-s2.0-0030614725
54. Rogers J. M., Diana G. D., McKinlay M. A., Pleconaril: a broad spectrum antipicornaviral agent. Advances in Experimental Medicine and Biology 1999 458 69 76 2-s2.0-0033281792
55. Rotbart H. A., Antiviral therapy for enteroviral infections. Pediatric Infectious Disease Journal 1999 18 7 632 633 2-s2.0-0032797014 10.1097/00006454-199907000-00013 (Pubitemid 29350332)
56. Parato K. A., Senger D., Forsyth P. A. J., Bell J. C., Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer 2005 5 12 965 976 2-s2.0-28844444483 10.1038/nrc1750 (Pubitemid 41766784)
57. Thirukkumaran C. M., Luider J. M., Stewart D. A., Cheng T., Lupichuk S. M., Nodwell M. J., Russell J. A., Auer I. A., Morris D. G., Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003 102 1 377 387 2-s2.0-0037902069 10.1182/blood-2002-08-2508 (Pubitemid 36759680)
58. Alain T., Hirasawa K., Pon K. J., Nishikawa S. G., Urbanski S. J., Auer Y., Lulder J., Martin A., Johnston R. N., Janowska-Wieczorek A., Lee P. W. K., Kossakowska A. E., Reovirus therapy of lymphoid malignancies. Blood 2002 100 12 4146 4153 2-s2.0-0036891871 10.1182/blood-2002-02-0503 (Pubitemid 35396882)
59. Stojdl D. F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J. C., Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Medicine 2000 6 7 821 825 2-s2.0-0033929057 10.1038/77558 (Pubitemid 30469434)
60. Deola S., Scaramuzza S., Birolo R. S., Cergnul M., Ficara F., Dando J., Voena C., Vai S., Monari M., Pogliani E., Corneo G., Peccatori J., Selleri S., Bordignon C., Roncarolo M. G., Aiuti A., Bregni M., Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. Journal of Translational Medicine 2007 5, article no. 35 2-s2.0-34548043039 10.1186/1479-5876-5-35 (Pubitemid 47278238)
61. Peng K. W., Ahmann G. J., Pham L., Greipp P. R., Cattaneo R., Russell S. J., Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001 98 7 2002 2007 2-s2.0-0035496901 10.1182/blood.V98.7.2002
62. Roscic-Mrkic B., Schwendener R. A., Odermatt B., Zuniga A., Pavlovic J., Billeter M. A., Cattaneo R., Roles of macrophages in measles virus infection of genetically modified mice. Journal of Virology 2001 75 7 3343 3351 2-s2.0-0035100882 10.1128/JVI.75.7.3343-3351.2001 (Pubitemid 32225897)
63. Peng K. W., Donovan K. A., Schneider U., Cattaneo R., Lust J. A., Russell S. J., Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003 101 7 2557 2562 2-s2.0-0037769825 10.1182/blood-2002-07-2195 (Pubitemid 36857613)
64. Myers R. M., Greiner S. M., Harvey M. E., Griesmann G., Kuffel M. J., Buhrow S. A., Reid J. M., Federspiel M., Ames M. M., Dingli D., Schweikart K., Welch A., Dispenzieri A., Peng K. W., Russell S. J., Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clinical Pharmacology and Therapeutics 2007 82 6 700 710 2-s2.0-36148993947 10.1038/sj.clpt.6100409 (Pubitemid 350114828)
65. Ong H. T., Timm M. M., Greipp P. R., Witzig T. E., Dispenzieri A., Russell S. J., Peng K. W., Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Experimental Hematology 2006 34 6 713 720 2-s2.0-33646686619 10.1016/j.exphem.2006.03.002 (Pubitemid 43737093)
66. Grote D., Russell S. J., Cornu T. I., Cattaneo R., Vile R., Poland G. A., Fielding A. K., Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001 97 12 3746 3754 2-s2.0-0035877990 10.1182/blood.V97.12.3746
67. Adachi Y., Reynolds P. N., Yamamoto M., Wang M., Takayama K., Matsubara S., Muramatsu T., Curiel D. T., A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Research 2001 61 21 7882 7888 2-s2.0-0035503241 (Pubitemid 33049379)
68. Senac J. S., Doronin K., Russell S. J., Jelinek D. F., Greipp P. R., Barry M. A., Infection and killing of multiple myeloma by adenoviruses. Human Gene Therapy 2010 21 2 179 190 2-s2.0-77249116368 10.1089/hum.2009.082
69. Deng H., Tang N., Stief A. E., Mehta N., Baig E., Head R., Sleep G., Yang X. Z., McKerlie C., Trudel S., Stewart A. K., McCart J. A., Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia 2008 22 12 2261 2264 2-s2.0-57849100045 10.1038/leu.2008.120
70. Esfandyari T., Tefferi A., Szmidt A., Alain T., Zwolak P., Lasho T., Lee P. W., Farassati F., Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. Molecular Oncology 2009 3 5-6 464 468 2-s2.0-70350574097 10.1016/j.molonc.2009.07.002
71. Angelova A. L., Aprahamian M., Balboni G., Delecluse H. J., Feederle R., Kiprianova I., Grekova S. P., Galabov A. S., Witzens-Harig M., Ho A. D., Rommelaere J., Raykov Z., Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Molecular Therapy 2009 17 7 1164 1172 2-s2.0-67649858805 10.1038/mt.2009.78
72. McFadden G., Poxvirus tropism. Nature Reviews Microbiology 2005 3 3 201 213 2-s2.0-14544284014 10.1038/nrmicro1099 (Pubitemid 40298220)
73. Wang G., Barrett J. W., Stanford M., Werden S. J., Johnston J. B., Gao X., Sun M., Cheng J. Q., McFadden G., Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proceedings of the National Academy of Sciences of the United States of America 2006 103 12 4640 4645 2-s2.0-33645240416 10.1073/pnas.0509341103
74. Wang F., Gao X., Barrett J. W., Shao Q., Bartee E., Mohamed M. R., Rahman M., Werden S., Irvine T., Cao J., Dekaban G. A., McFadden G., RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathogens 2008 4 7 2-s2.0-48249149162 10.1371/journal.ppat.1000099 e1000099
75. Bartee E., McFadden G., Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon- β Cytokine 2009 47 3 199 205 2-s2.0-68949163770 10.1016/j.cyto.2009.06.006
76. Kawa A., Arakawa S., The effect of attenuated vaccinia virus AS strain on multiple myeloma: a case report. Japanese Journal of Experimental Medicine 1987 57 1 79 81 2-s2.0-0023227802 (Pubitemid 17067625)